Dr. Rosmarin highlights his presentation from AAD 2025, in which he reviewed the optimal method for using ruxolitinib cream for vitiligo, touching on setting patient expectations, pigmentation timelines, and response rates among patient sub-groups, and navigating any potential side effects.
Dr. Lio discusses the nuances of approaching patient questions and misconceptions around dietary modifications and restrictions for atopic dermatitis.
PLAY
Emmy Graber, MD: New Efficacy Evidence for Acne and Rosacea Devices
Dr. Graber discusses new evidence supporting the use of 1726nm lasers for the treatment of inflammatory and non-inflammatory acne, as well as pulsed-dye laser and...
PLAY
Steve Daveluy, MD: Using Cryoinsufflation in Patients with Hidradenitis Suppurativa
Dr. Daveluy provides tips and guidance for using cryoinsufflation in the treatment of HS.
PLAY
Christopher Bunick, MD, PhD: Clearing Up Questions Around Benzene in Benzoyl Peroxide Products
Dr. Bunick explores the discussion on benzene in benzoyl peroxide (BPO) products, including questions around ensuring products are meeting FDA regulations, what dermatologists can do...
PLAY
Christopher Bunick, MD, PhD: Antibiotic Update for Acne and Rosacea
Dr. Bunick provides a comprehensive update on using antibiotics for the treatment of acne and rosacea, including influences on gut health, antibiotic resistance, and efficacy...
PLAY
Lisa Swanson, MD: What’s New in Pediatric Dermatology at AAD 2025
Dr. Swanson discusses the most exciting developments across pediatric atopic dermatitis, psoriasis, alopecia areata, vitiligo, and infantile hemangiomas.
PLAYThe AAD © Brand and Content are created by the American Academy of Dermatology “All rights reserved.” Any reproduction or republication is strictly prohibited without prior authorization.
The content of the 2025 AAD Annual Meeting (the “Content”) is copyrighted by the American Academy of Dermatology (“AAD”). The Works, JCADTV Coverage from the 2025 AAD Annual Meeting, are made up of coverage interviews and summaries and are created from the Content of the AAD under a license between the AAD and Matrix Medical Communications (“MATRIX MEDICAL COMMUNICATIONS”), and MATRIX MEDICAL COMMUNICATIONS is solely responsible for their content. The license of any content by the AAD does not constitute or imply endorsement of any company or its goods, services, or written work products, and the AAD is not responsible for any errors or omissions in the translation or reproduction of the content.
